The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial

EuroIntervention 2016;12:1102-1107 published online ahead of print August 2016. DOI: 10.4244/EIJY16M08_01

1. Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Massy, France; 2. Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 3. Medical Center Leeuwarden, Leeuwarden, The Netherlands; 4. AMC Heart Center, Academic Medical Center,

Aims: The one-year randomised data of the ABSORB II trial showed that the everolimus-eluting bioresorbable scaffold and the everolimus-eluting metallic stent were comparable for the compo

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article

Invasive strategies and outcomes for non-ST-segment elevation acute coronary syndromes: a twelve-year experience from SWEDEHEART